Angiotech and Boston Scientific welcome journal article noting important differences between drug-eluting stent brands
11 Mai 2009 - 10:44PM
PR Newswire (US)
VANCOUVER, May 11 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today
announced its corporate partner, Boston Scientific Corporation, has
welcomed the publication of an article in the current edition of
the Journal of the American College of Cardiology (JACC) reviewing
data on more than 19,000 patients from the Swedish national
registry who were evaluated for restenosis, or the re-narrowing or
arteries after percutaneous coronary intervention (PCI). The
article reported that patients who received a TAXUS(R) Liberte(R)
Paclitaxel-Eluting Stent had numerically lower incidences of repeat
procedures to treat restenosis at two years as compared to patients
treated with 'olimus-based drug-eluting stents (DES), including
Cordis' Cypher(R) Stent and Medtronic's Endeavor(R) Stent. In the
patients with diabetes, the TAXUS Liberte Stent demonstrated a
statistically significant lower restenosis rate compared to the
Endeavor Stent, which had more than two times the risk of repeat
procedures. The Swedish Coronary Angiography and Angioplasty
Registry holds data on all patients undergoing PCI in Sweden. The
objective of this independent study was to evaluate restenosis
rates of drug-eluting stents in patients with and without diabetes
in a real-world setting. The JACC article reported that both the
TAXUS Liberte Stent and Boston Scientific's first-generation DES --
the TAXUS(R) Express(R) Stent -- were the only stents in the study
showing no increased risk of restenosis for patients with diabetes
as compared to those without diabetes. Both the Cypher Stent and
Endeavor Stent showed significant increased risk of restenosis in
patients with diabetes. In addition, the study showed that the
TAXUS Liberte Stent had an approximately 23 percent lower
restenosis rate at two years compared to the prior-generation TAXUS
Express Stent. The authors concluded that "There seem to be
important differences between different brands of DES."(1) "The
results of this study are noteworthy for TAXUS Liberte, which
compared favorably in rates of repeat procedures to both 'olimus
stents," said Donald S. Baim, M.D., Chief Medical and Scientific
Officer of Boston Scientific. "The findings presented in the
article are consistent with our own clinical trial observations,
including recently published ARRIVE and ATLAS data, and may reflect
the different mechanism of action for paclitaxel compared to the
'olimus agents used in the other drug-eluting stents. The newer and
thinner-strut TAXUS Liberte Stent performed better than the TAXUS
Express Stent in reducing restenosis." The Swedish registry study
included four DES brands: TAXUS Liberte, TAXUS Express, Cypher and
Endeavor. In total, the registry included 35,478 DES implants
during 22,962 procedures in 19,004 patients, with 1,807 restenoses
reported over a mean 29-month follow-up period. For the entire
study population, the repeat revascularization rate per stent was
3.5 percent after one year and 4.9 percent after two years.
Overall, the adjusted risk of restenosis was 1.23 times higher in
patients with diabetes than in patients without diabetes. In
patients with diabetes, restenosis was higher in the non-TAXUS
Stents. The sirolimus-eluting Cypher Stent and the
zotorolimus-eluting Endeavor Stent had higher restenosis rates in
patients with diabetes compared with those in patients without
diabetes (1.25 times and 1.77 times, respectively). TAXUS Stents
have been evaluated by the industry's most extensive randomized,
controlled clinical trial program, with follow-up to five years in
some cases. These trial results have been supplemented by data on
more than 35,000 patients enrolled in post-approval registries. To
date, approximately 11 million Boston Scientific stents have been
implanted globally, making them the world's most frequently used
stents. The TAXUS Liberte Paclitaxel-Eluting Coronary Stent System
received U.S. Food and Drug Administration approval in October
2008, and received European CE Mark approval for use in patients
with diabetes in December 2007. In the U.S., the TAXUS Stents are
not specifically indicated for use in patients with diabetes. (1) J
Am Coll Cardiol 2009;53:1660-7 Forward Looking Statements
-------------------------- Statements contained in this press
release that are not based on historical fact, including without
limitation statements containing the words "believes," "may,"
"plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and "forward-looking
information" within the meaning of applicable Canadian securities
laws. All such statements are made pursuant to the "safe harbor"
provisions of applicable securities legislation. Forward-looking
statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our
strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our
operations, research, development, product and drug development.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among
others, the following: general economic and business conditions,
both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products
sold by our partners; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development and to expand manufacturing and
commercialization activities or consummate acquisitions; and any
other factors that may affect performance. In addition, our
business is subject to certain operating risks that may cause the
actual results expressed or implied by the forward-looking
statements in this press release to differ materially from our
actual results. These operating risks include: our ability to
attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products;
changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; and any other
factors referenced in our other filings with the Securities and
Exchange Commission ("SEC") and applicable Canadian regulatory
authorities. For a more thorough discussion of the risks associated
with our business, see the "Risk Factors" section in our annual
report for the year ended December 31, 2008 filed with the SEC on
Form 10-K, and our quarterly report for the three months ended
March 31, 2009 filed with the SEC on Form 10-Q. Given these
uncertainties, assumptions and risk factors, readers are cautioned
not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any
such factors or to publicly announce the result of any revisions to
any of the forward-looking statements contained in this press
release to reflect future results, events or developments. (C) 2009
Angiotech Pharmaceuticals, Inc. All Rights Reserved. About
Angiotech Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a
global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and
markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. DATASOURCE: Angiotech Pharmaceuticals,
Inc. CONTACT: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Okt 2023 bis Okt 2024